Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nerve Net | 18 | 2018 | 105 | 2.600 |
Why?
|
| Connectome | 18 | 2018 | 87 | 2.540 |
Why?
|
| Brain Neoplasms | 15 | 2022 | 297 | 2.470 |
Why?
|
| Glioblastoma | 9 | 2022 | 100 | 1.960 |
Why?
|
| White Matter | 10 | 2018 | 89 | 1.350 |
Why?
|
| Medulloblastoma | 4 | 2016 | 18 | 1.210 |
Why?
|
| Cerebellar Neoplasms | 4 | 2016 | 28 | 1.190 |
Why?
|
| Parietal Lobe | 3 | 2018 | 26 | 0.800 |
Why?
|
| Neuroimaging | 18 | 2018 | 86 | 0.690 |
Why?
|
| Neural Pathways | 18 | 2018 | 118 | 0.680 |
Why?
|
| Diffusion Tensor Imaging | 17 | 2018 | 79 | 0.650 |
Why?
|
| Magnetic Resonance Imaging | 21 | 2018 | 810 | 0.650 |
Why?
|
| Occipital Lobe | 4 | 2018 | 21 | 0.630 |
Why?
|
| Frontal Lobe | 4 | 2018 | 42 | 0.620 |
Why?
|
| Ataxia | 2 | 2014 | 7 | 0.580 |
Why?
|
| Dizziness | 2 | 2014 | 10 | 0.580 |
Why?
|
| Glioma | 4 | 2021 | 118 | 0.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 375 | 0.530 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 27 | 0.510 |
Why?
|
| Alien Hand Syndrome | 1 | 2015 | 2 | 0.500 |
Why?
|
| Oligodendroglioma | 1 | 2015 | 9 | 0.500 |
Why?
|
| Gyrus Cinguli | 3 | 2018 | 33 | 0.470 |
Why?
|
| Humans | 41 | 2022 | 27125 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 312 | 0.410 |
Why?
|
| Neurosurgical Procedures | 4 | 2020 | 217 | 0.390 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2021 | 77 | 0.340 |
Why?
|
| Cell Movement | 2 | 2022 | 353 | 0.330 |
Why?
|
| Astrocytoma | 2 | 2020 | 35 | 0.320 |
Why?
|
| Nerve Fibers | 8 | 2018 | 53 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 3 | 2021 | 317 | 0.310 |
Why?
|
| Functional Laterality | 2 | 2018 | 62 | 0.310 |
Why?
|
| Cell Line, Tumor | 6 | 2022 | 1267 | 0.310 |
Why?
|
| Temporal Lobe | 2 | 2018 | 31 | 0.300 |
Why?
|
| Neoplasms, Neuroepithelial | 2 | 2018 | 9 | 0.280 |
Why?
|
| Seizures | 2 | 2015 | 46 | 0.250 |
Why?
|
| Brain | 2 | 2018 | 707 | 0.210 |
Why?
|
| Male | 13 | 2020 | 13008 | 0.210 |
Why?
|
| Mechanical Phenomena | 1 | 2022 | 17 | 0.200 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 250 | 0.190 |
Why?
|
| Extracellular Matrix | 1 | 2022 | 110 | 0.180 |
Why?
|
| Apraxias | 1 | 2020 | 2 | 0.180 |
Why?
|
| Ampicillin | 1 | 2020 | 13 | 0.180 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2020 | 10 | 0.180 |
Why?
|
| Annexin A5 | 1 | 2020 | 24 | 0.180 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 154 | 0.180 |
Why?
|
| Gliosarcoma | 1 | 2020 | 3 | 0.170 |
Why?
|
| Motor Cortex | 1 | 2020 | 46 | 0.170 |
Why?
|
| Listeria monocytogenes | 1 | 2020 | 58 | 0.170 |
Why?
|
| Treatment Outcome | 5 | 2020 | 2283 | 0.170 |
Why?
|
| Microtechnology | 1 | 2019 | 4 | 0.170 |
Why?
|
| Bevacizumab | 2 | 2020 | 93 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 139 | 0.170 |
Why?
|
| Dacarbazine | 2 | 2016 | 14 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 185 | 0.160 |
Why?
|
| Sensorimotor Cortex | 1 | 2018 | 7 | 0.160 |
Why?
|
| Adult | 8 | 2020 | 7494 | 0.160 |
Why?
|
| Cell Proliferation | 3 | 2021 | 773 | 0.160 |
Why?
|
| Cerebrum | 1 | 2018 | 14 | 0.160 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 79 | 0.150 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 27 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 292 | 0.150 |
Why?
|
| Escherichia coli | 1 | 2020 | 329 | 0.150 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 134 | 0.150 |
Why?
|
| Transcription Factors | 1 | 2021 | 514 | 0.140 |
Why?
|
| Glutarates | 1 | 2016 | 3 | 0.140 |
Why?
|
| Brain Chemistry | 1 | 2016 | 22 | 0.140 |
Why?
|
| Magnetic Field Therapy | 1 | 2016 | 3 | 0.140 |
Why?
|
| Female | 9 | 2020 | 14625 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 497 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 104 | 0.130 |
Why?
|
| Camptothecin | 1 | 2016 | 15 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2016 | 179 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 144 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2020 | 606 | 0.130 |
Why?
|
| Ganglioglioma | 1 | 2015 | 4 | 0.130 |
Why?
|
| Complement C3 | 1 | 2015 | 21 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 234 | 0.120 |
Why?
|
| Young Adult | 3 | 2016 | 2628 | 0.110 |
Why?
|
| Middle Aged | 7 | 2020 | 6901 | 0.110 |
Why?
|
| Biomarkers | 1 | 2016 | 736 | 0.110 |
Why?
|
| Aged | 5 | 2020 | 5217 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 246 | 0.070 |
Why?
|
| Prognosis | 2 | 2021 | 762 | 0.070 |
Why?
|
| Mice | 3 | 2021 | 4464 | 0.060 |
Why?
|
| Animals | 4 | 2021 | 10063 | 0.060 |
Why?
|
| Adolescent | 3 | 2016 | 2990 | 0.060 |
Why?
|
| Benzenesulfonates | 1 | 2021 | 18 | 0.050 |
Why?
|
| Imines | 1 | 2021 | 21 | 0.050 |
Why?
|
| Nitrogen Oxides | 1 | 2021 | 40 | 0.050 |
Why?
|
| Histones | 1 | 2021 | 90 | 0.050 |
Why?
|
| Phosphatidylserines | 1 | 2020 | 20 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2020 | 50 | 0.040 |
Why?
|
| Phospholipids | 1 | 2020 | 75 | 0.040 |
Why?
|
| Placebos | 1 | 2020 | 45 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 135 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2018 | 2461 | 0.040 |
Why?
|
| Chickens | 1 | 2019 | 59 | 0.040 |
Why?
|
| Electricity | 1 | 2019 | 6 | 0.040 |
Why?
|
| Receptors, Notch | 1 | 2019 | 44 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 148 | 0.040 |
Why?
|
| Porosity | 1 | 2019 | 38 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 108 | 0.040 |
Why?
|
| Microvessels | 1 | 2019 | 86 | 0.040 |
Why?
|
| Child | 2 | 2015 | 2164 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 229 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 405 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2020 | 975 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 821 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 225 | 0.040 |
Why?
|
| Phenotype | 1 | 2019 | 665 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 17 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2016 | 20 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2016 | 30 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 310 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2017 | 312 | 0.030 |
Why?
|
| PubMed | 1 | 2015 | 8 | 0.030 |
Why?
|
| Receptors, Complement | 1 | 2015 | 6 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 404 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2016 | 199 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 80 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 240 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 131 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 751 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 986 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 195 | 0.030 |
Why?
|
| Algorithms | 1 | 2016 | 421 | 0.030 |
Why?
|
| Apoptosis | 1 | 2017 | 738 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2016 | 1223 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 1935 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 368 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 1494 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 970 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 1098 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 1405 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 1372 | 0.020 |
Why?
|